How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,375 results for

Cushing Response

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

241. Management of Uterine Fibroids

), Rockville, MD (Contract No. 290-2015-00003-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. None of the investigators have any affiliations or financial involvement that conflicts with the material presented

2017 Effective Health Care Program (AHRQ)

242. British Association of Dermatologists guidelines for the management of pemphigus vulgaris

a bone density scan early in the course of treatment may be needed. In anticipation of using an adjuvant immunosuppressant, appropriate recommended additional investigations and vacci- nations should be undertaken. A baseline measure of disease activity (see section 91) and quality of life, supplemented by IIF and ELISA titres if facilities exist, will be useful for disease monitoring and judging treatment responses (see sections 90–92). 9.0 Disease monitoring Decisions concerning ongoing disease (...) outcomesarein?uencedbytheintensityofinitialtreatment. 57,74 If there is no response within 5–7 days, it is suggested that the dose should be increased in 50–100% increments until dis- ease control is achieved, de?ned as no new lesions and the onset of healing in pre-existing ones. 9,61,65,71,75 If prednisolone doses above 1 mg kg 1 per day are required, pulsed intravenous cor- ticosteroids should be considered. Treatment failure for oral corticosteroids has been de?ned by international consensus as failure

2017 British Association of Dermatologists

243. Interventions Targeting Sensory Challenges in Children with Autism Spectrum Disorder - An Update

-2015-00003-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report. The information (...) and cerebellum of three older men with fragile X syndrome. Mol Autism. 2011;2(1):2. doi: 10.1186/2040-2392-2-2. PMID: 21303513.X-1 653. Greer RD, Pistoljevic N, Cahill C, et al. Effects of conditioning voices as reinforcers for listener responses on rate of learning, awareness, and preferences for listening to stories in preschoolers with autism. Anal Verbal Behav. 2011;27(1):103- 24. PMID: 22532758.X-1, X-3, X-4 D-56 654. Griffith GM, Hastings RP, Oliver C, et al. Psychological well-being in parents

2017 Effective Health Care Program (AHRQ)

244. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline Full Text available with Trip Pro

gender. (2 |⊕⊕○○) 3.4. We suggest that endocrinologists provide education to transgender individuals undergoing treatment about the onset and time course of physical changes induced by sex hormone treatment. (2 |⊕○○○) 4.0 Adverse outcome prevention and long-term care 4.1. We suggest regular clinical evaluation for physical changes and potential adverse changes in response to sex steroid hormones and laboratory monitoring of sex steroid hormone levels every 3 months during the first year of hormone (...) of including a total hysterectomy and oophorectomy as part of gender-affirming surgery. (Ungraded Good Practice Statement) 5.0 Surgery for sex reassignment and gender confirmation 5.1. We recommend that a patient pursue genital gender-affirming surgery only after the MHP and the clinician responsible for endocrine transition therapy both agree that surgery is medically necessary and would benefit the patient’s overall health and/or well-being. (1 |⊕⊕○○) 5.2. We advise that clinicians approve genital gender

2017 Pediatric Endocrine Society

245. Clinical Practice Guidelines on Hypertension

), as they will require two or more drugs for adequate BP control. Grade B, Level 2 + 33 27 Initiate treatment at low doses of drugs, either singly or as a two-drug combination, to minimise side effects. Grade D, Level 4 33 28 If an adequate dose of the first drug used demonstrated limited response or was poorly- tolerated, change to a different drug class instead of increasing the dose of the first drug. Grade A, Level 1 + 33 29 Add a second drug when a single drug fails to achieve target BP. Grade B, Level 1 + 34 6 (...) or angiotensin II receptor blocker (ARB) suggests high circulating levels of renin and angiotensin II. In this situation, look out for bilateral renal artery stenosis. 3,9,10 The identifiable secondary causes of hypertension are listed in Table 4. Table 4 Identifiable secondary causes of hypertension Identifiable secondary causes of hypertension 1. Drug-related and substance-related* causes 2. Chronic kidney disease 3. Renal artery stenosis 4. Primary hyperaldosteronism 5. Hypercortisolism (Cushing’s

2017 Ministry of Health, Singapore

246. Cervical Cancer: ESMO Clinical Practice Guidelines

invasive cervical cancers but has a particular propensity to spread distantly, which is similar to small-cell carcinoma of the lung. As a result, patients can present with systemic symptoms such as weight loss. In addition, patients may present with a paraneoplastic syndrome such as the syn- drome of inappropriate antidiuretic hormone secretion (SIADH), Cushing syndrome, hypercalcaemia or a neurological disorder. The most commonly involved organs include the liver, adrenals, bone, bone marrow (...) if the patient has a performance status (PS) 2 and no formal contraindications. Cisplatin 50 mg/m 2 every 3 weeks was, for two decades, the standard of care. However, the global ef- ?cacy was disappointing due to a low response rate (20%), short median PFS (2.8–3.2 months) and OS (6.2–8.0 months). Cisplatin-based doublets with topotecan or paclitaxel have demonstrated superiority to cisplatin monotherapy in terms of response rate and PFS [43, 44]. Cisplatin combined with topote- can showed superior OS

2017 European Society for Medical Oncology

247. Special Endocrine Testing

testing, with rare exception, is indicated for the investigation of hypercalcemia with concomitantly low parathyroid hormone (PTH) only and is not indicated for monitoring patients receiving calcitriol. Insulin testing is primarily useful for investigation of spontaneous hypoglycemia or to help distinguish type I diabetes from type II diabetes, but not for establishment of insulin resistance. The utility of salivary hormone testing in any clinical context is limited to Cushing Syndrome screening using (...) and plasma renin activity after 1-2 hours ambulation and before 10 AM. Numerous physiological states and medications interfere with sensitivity and specificity of screening. Renin MSP cost: $63.87 – $98.11 Indications Non-Indications Investigation of secondary causes of hypertension: primary aldosteronism and renal artery stenosis. Monitoring of CAH and mineralocorticoid supplementation in Addison’s Disease. Cortisol, 24-hour urine free Indications Non-Indications Used for targeted screening for Cushing

2016 Clinical Practice Guidelines and Protocols in British Columbia

248. CVD Prevention in Clinical Practice

permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC. Disclaimer . The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction (...) not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order

2016 European Society of Cardiology

249. Pharmacist-led Chronic Disease Management: A Systematic Review of Effectiveness and Harms Compared to Usual Care

. The ESP CC establishes standard operating procedures for the production of evidence synthesis reports; facilitates a national topic nomination, prioritization, and selection process; manages the research portfolio of each Center; facilitates editorial review processes; ensures methodological consistency and quality of products; produces “rapid response evidence briefs” at the request of VHA senior leadership; collaborates with HSR&D Center for Information Dissemination and Education Resources (CIDER (...) ; 2015. This report is based on research conducted by the Evidence-based Synthesis Program (ESP) Center located at the Minneapolis VA Medical Center, Minneapolis, MN, funded by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research Initiative. The findings and conclusions in this document are those of the author(s) who are responsible for its contents; the findings and conclusions do not necessarily represent the views

2016 Veterans Affairs Evidence-based Synthesis Program Reports

250. Neofordex - dexamethasone. To treat adults with multiple myeloma

Transplantation AUC Area Under the Curve Bor Bortezomib BMI Body Mass Index BMSC Bone marrow stromal cells BTD PACE Bortezomib, Thalidomide, and Dexamethasone plus Cisplatin, Doxorubicin, Cyclophosphamide, and Etoposide CEP Certificate of Suitability of the EP CHMP Committee for Human Medicinal Products CI Confidence Interval CL Total Clearance Cmax Average Maximum Concentration CR Complete Response CTD Cyclophosphamide, Thalidomide, and Dexamethasone CTDa Attenuated Cyclophosphamide, Thalidomide (...) , and Dexamethasone CVAD Cyclophosphamide, Vincristine, Adriamycin and Dexamethasone CYP Cytochrome DCEP Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin, Dex Dexamethasone DOR Duration of Response EBMT European Group for Blood and Marrow Transplantation EC European Commission ECOG Eastern Cooperative Oncology Group EDQM European Directorate for the Quality of Medicines EFS Event Free Survival GCP Good Clinical Practice GD Gestation days HPLC High performance liquid chromatography HR Hazard Ratio

2016 European Medicines Agency - EPARs

251. Osteoporosis: assessing the risk of fragility fracture

Osteoporosis: assessing the risk of fragility fracture Osteoporosis: assessing the risk of Osteoporosis: assessing the risk of fr fragility fr agility fracture acture Clinical guideline Published: 8 August 2012 nice.org.uk/guidance/cg146 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful (...) consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian

2012 National Institute for Health and Clinical Excellence - Clinical Guidelines

252. Corluxin - mifepristone

). In addition reductions in fasting blood glucose, 2 hour post prandial glucose and insulin reflect the changes in AUC and are strongly supportive of the efficacy of Corluxin in managing hyperglycaemia in those with Cushing’s syndrome with DM or impaired glucose tolerance. The applicant has recalculated response rates for the primary endpoint in the DM population using the ITT population and two sided 95% confidence intervals. The lower bound for the 95% CI in the ITT population is 32.5% which is above (...) and symptoms of endogenous Cushing’s syndrome in adults is not approvable since "major objections" have been identified to which the applicant has not responded at the time of withdrawal of the application, which preclude a recommendation for marketing authorisation at the present time. The major objections precluding a recommendation of marketing authorisation pertain to the following principal deficiencies: Quality 1. Clear documentary evidence confirming inspection of the site of finished product

2015 European Medicines Agency - EPARs

253. Saxenda - liraglutide

. Pharmacokinetics 24 2.4.3. Pharmacodynamics 27 2.4.4. Discussion on clinical pharmacology 30 2.4.5. Conclusions on clinical pharmacology 32 2.5. Clinical efficacy 33 2.5.1. Dose response study 33 2.5.2. Dose response and main studies 33 2.5.3. Discussion on clinical efficacy 59 2.5.4. Conclusions on the clinical efficacy 63 2.6. Clinical safety 63 2.6.1. Discussion on clinical safety 75 2.6.2. Conclusions on the clinical safety 78 2.7. Pharmacovigilance 79 2.8. Risk Management Plan 79 2.9. Product information (...) Denmark Novo Nordisk A/S Novo Alle, 2880 Bagsvaerd Denmark Manufacturers responsible for batch release Novo Nordisk A/S Novo Alle 2880 Bagsvaerd DENMARK 1.3. Steps taken for the assessment of the product The Rapporteur and Co-Rapporteur appointed by the CHMP were: Rapporteur: Pieter de Graeff Co-Rapporteur: Jens Heisterberg CHMP Peer reviewer:Ondrej Slanar • The application was received by the EMA on 20 December 2013. • The procedure started on 22 January 2014. • The Rapporteur's first Assessment

2015 European Medicines Agency - EPARs

254. Anesthesia Information Management Systems for Patients Undergoing Surgery

Anesthesia Information Management Systems for Patients Undergoing Surgery Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should (...) be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

255. Hypercholesterolaemia - familial

occur in people with FH, but they are less specific. [ ; ; ; ] Secondary hypercholesterolaemia Causes of secondary hypercholesterolaemia The following conditions may cause hypercholesterolaemia (without hypertriglyceridaemia): Hypothyroidism. See the CKS topic on for more information. Cholestatic liver disease (such as primary biliary cirrhosis). Nephrotic syndrome. Cushing's syndrome. Anorexia nervosa. See the CKS topic on for more information. The use of certain drugs, including androgens (...) % from baseline on the basis of the ASAP study, a randomized, double-blind trial in 325 adults with FH, as this was the therapeutic response associated with lack of progression of atherosclerosis, but advises that clinicians should use their expert judgment when individualizing treatment [ ]. CKS is aware that this treatment target differs from that in the NICE guideline on lipid modification [ ], which gives a treatment aim of 40% reduction in non high-density lipoprotein (HDL) cholesterol. However

2019 NICE Clinical Knowledge Summaries

256. Erectile dysfunction

multiple sclerosis, Parkinson’s disease); anatomical (for example Peyronie’s disease, hypospadias), or hormonal (for example hypogonadism, hyper-and hypothyroidism, Cushing’s disease). Psychogenic causes may be situational (for example due to psychiatric illness [such as depression]) or generalized (for example due to lack of arousability). Drugs that can cause erectile dysfunction include antihypertensives, antipsychotics, and antidepressants. The risk factors for erectile dysfunction are similar (...) , pelvis or spine; abnormality of the penis or testicles; or no response to maximum dose of at least two PDE-5 inhibitors. To endocrinology — if hypogonadism is suspected (abnormal serum testosterone). To cardiology — if the man has CVD that makes sexual activity unsafe or contraindicates PDE-5 inhibitor use. To mental health services — if an underlying psychogenic cause is suspected or the man has severe mental distress. Have I got the right topic? Have I got the right topic? From age 18 years onwards

2019 NICE Clinical Knowledge Summaries

257. Bipolar disorder

with bipolar disorder include: Statement 1. Adults presenting in primary care with symptoms of depression are offered a referral for a specialist mental health assessment if they have experienced overactivity or disinhibited behaviour lasting 4 days or more. Statement 2. Adults with bipolar disorder have their early warning symptoms and triggers of relapse, preferred response during relapse and personal recovery goals specified in their care plan. Statement 3. Carers of adults with bipolar disorder (...) and if symptoms subside within 7 days. Organic brain disease caused by, for example, progressive frontal lobe dementia, cerebrovascular disease, multiple sclerosis, AIDS, epilepsy, systemic lupus erythematosus, encephalitis, or a space-occupying lesion. Iatrogenic causes, for example, use of antidepressants, corticosteroids, levodopa, pramipexole, and prescribed stimulants (such as methylphenidate). Metabolic disorders, for example, hyperthyroidism, Cushing's disease, Addison's disease, vitamin B 12

2019 NICE Clinical Knowledge Summaries

258. Neurosteroidogenesis is required for the physiological response to stress: role of neurosteroid-sensitive GABAA receptors Full Text available with Trip Pro

Neurosteroidogenesis is required for the physiological response to stress: role of neurosteroid-sensitive GABAA receptors The hypothalamic-pituitary-adrenal (HPA) axis, which mediates the body's response to stress, is largely under GABAergic control. Here we demonstrate that corticotropin-releasing hormone (CRH) neurons are modulated by the stress-derived neurosteroid, tetrahydrodeoxycorticosterone (THDOC), acting on δ subunit-containing GABA(A) receptors (GABA(A)Rs). Under normal conditions (...) conditions. Interestingly, blocking neurosteroidogenesis with finasteride is sufficient to block the stress-induced elevations in corticosterone and prevent stress-induced anxiety-like behaviors in mice. These data demonstrate that positive feedback of neurosteroids onto CRH neurons is required to mount the physiological response to stress. Further, GABA(A)R δ subunit-containing receptors and phosphorylation of KCC2 residue Ser940 may be novel targets for control of the stress response, which has

2011 The Journal of Neuroscience

259. Effect of Oxytocin on Stress Response in Cocaine-dependent Individuals

. Subjects with Addison's disease, Cushing's disease or other diseases of the adrenal cortex likely to affect hormonal/neuroendocrine status. Subjects with a history of or current psychotic disorder or bipolar affective disorder as these may interfere with subjective measurements. Subjects with current major depressive disorder or post-traumatic stress disorder as these disorders are associated with characteristic changes in stress response. Subjects receiving synthetic glucocorticoid therapy, any (...) Effect of Oxytocin on Stress Response in Cocaine-dependent Individuals Effect of Oxytocin on Stress Response in Cocaine-dependent Individuals - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effect

2011 Clinical Trials

260. The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study

The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01323608 Recruitment Status : Unknown Verified April 2011 by Weill Medical College of Cornell University

2011 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>